Gilead Sciences

This Earth Day, we’re recognizing the people behind our commitment to sustainable health. At Gilead, teams across the company strive to embed responsible practices into how we operate every day. From scientists and facilities teams to procurement and global supply chain partners, our colleagues are reducing waste, conserving resources, and strengthening partnerships further embedding sustainability into how we discover, manufacture, and deliver medicines while supporting communities around the world. That work recently earned us TRUE Gold Zero Waste certification, after assessment of our waste reduction and resource efficiency efforts, at our Foster City headquarter campus. Explore our 2025 Responsible Business and Impact Report to see our sustainability teams in action—and learn more about the progress behind this achievement: https://ow.ly/e9AR50YO6AN

Since setting our corporate strategy in 2019, we’ve been building toward a bold, long‑term vision for Gilead. From individual patients to entire populations, we're delivering exponential impact now while relentlessly pursuing what's next. Read our 2025 Responsible Business and Impact Report to see how the past year marked accelerated momentum toward our 2030 ambitions, with continued progress ahead. https://lnkd.in/gqj7EJsk

For 20 years, this conference has brought together patients, caregivers and experts for a powerful weekend focused on connection, education and support for the metastatic breast cancer (MBC) community.    We’re proud to work alongside Living Beyond Breast Cancer in advancing understanding, improving outcomes and supporting every person navigating #MBC.

The oncology field has seen what durable responses to cancer can look like. Making them available to far more patients, across more cancer types, is what will continue to shape the next phase of research. As the oncology research community gathers at #AACR26 this week, Jackson Egen and Priti Hegde discuss how Gilead and Kite Pharma are approaching that challenge in a recent conversation with STAT.

Cancer rarely stays the same, especially in how it resists treatment. Advancing transformative therapies that can stay ahead of it is what brings our research teams to the American Association for Cancer Research Annual Meeting in San Diego. Swipe to see what our oncology leaders Jackson Egen and Priti Hegde are watching this week. #AACR26

At SEMAFOR World Economy 2026, Daniel O'Day, our Chairman & CEO, spoke about what it takes to address the world’s biggest health challenges. Our focus remains on ensuring breakthrough medicines reach the people who need them the most, while building a future where HIV, cancer and autoimmune conditions can be fundamentally transformed.    "I believe in my lifetime we will be able to talk about HIV in the past tense. That goal animates everyone who works at Gilead.” -- Daniel O’Day, Chairman & CEO The full conversation with Alexis Akwagyiram can be found on SEMAFOR’s YouTube channel.

Young women living with metastatic triple-negative breast cancer (mTNBC) deserve support that goes beyond treatment, including deeper connections, emotional support and accessible resources. Whole-patient care helps empower people every step of the way.

#GileadNews: Grammy award-winning artist Ciara is using her platform and voice with purpose. By stepping up to join the power of music with the power of medicine, she's helping spark conversations, break stigma and expand awareness around HIV prevention. Together, through education and innovation, we can help protect more people and move closer to ending HIV. Read more: https://time.com/ #HIVPrevention #PrEP #HealthEquity

#GileadNews: Today, we’re announcing that the U.S. Department of State, #PEPFAR and The Global Fund will further invest in our HIV prevention medication to expand access for up to an additional one million people, bringing the total commitment up to three million people in high-incidence, resource-limited countries through 2028. Read more: https://gilead.inc/41BSQY3

A tumor doesn’t just resist treatment; it actively works to suppress the immune response that makes treatment effective. Pairing cell therapy with an approach that addresses that dynamic could mean more durable outcomes for more patients.  Read more on how we’re advancing cell therapy and other targeted mechanisms to fight cancer in a new article in STAT News: https://lnkd.in/g3RWJkzB